UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16

OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of May, 2023

 

Commission File Number: 001-36582

 

Altamira Therapeutics Ltd.

(Translation of registrant’s name into English)

 

Clarendon House, 2 Church Street

Hamilton HM 11, Bermuda

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F ☒ Form 40-F ☐

 

 

 

 

 

 

EXHIBIT INDEX

 

Exhibit
Number		   Description
     
99.1   Press release, dated as of May 16, 2023

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Altamira Therapeutics Ltd.  
   
By: /s/ Thomas Meyer  
  Name:  Thomas Meyer  
  Title: Chief Executive Officer  

 

Date: May 16, 2023

 

 

2

 

 

Altamira Therapeutics (NASDAQ:CYTO)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025 Haga Click aquí para más Gráficas Altamira Therapeutics.
Altamira Therapeutics (NASDAQ:CYTO)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025 Haga Click aquí para más Gráficas Altamira Therapeutics.